Sulfated oligosaccharides and tumor: Promoter or inhibitor?

Panminerva Medica

Volumn 48, Issue 1, 2006, Pages 27-31

  Wu, X Z ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Carcinogenesis; Chondroitin sulfate; Heparan sulfate; Metastases; Sulfated oligosaccharides

Indexed keywords

CARCINOGEN; OLIGOSACCHARIDE; SULFATE;

CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; HUMAN; METABOLISM; METASTASIS; NEOPLASM; REVIEW;

CARCINOGENS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; OLIGOSACCHARIDES; SULFATES;

EID: 33745010457     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476.
2. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-77.
3. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
4. Klerk CP, Smorenburg SM, Otten HM, Hastie TJ, Garber AM. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.
5. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 2002;62:4282-8.
6. Ida M, Kamada A. Changes in glycosaminoglycan characteristics during progression of a human gingival carcinoma xenograft line in nude mice. J Osaka Dent Univ 1995;29:39-50.
7. Wolanska M, Sobolewski K, Bankowski E, Chyczewski L. Alterations in glycosaminoglycan composition of methylcholanthrene-induced sarcoma at various stages of the tumour growth. Folia Histochem Cytobiol 1996;34:21-6.
8. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochem Biophys Res Commun 1989;162:189-97.
9. Bertolotto A, Magrassi ML, Orsi L, Sitia C, Schiffer D. Glycosaminoglycan changes in human gliomas. A biochemical study. J Neurooncol 1986;4:43-8.
10. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 1998;273:51-7.
11. Kojima J, Nakamura N, Kanatani M, Akiyama M. Glycosaminoglycans in 3′-methyl-4-dimethylaminoazobenzene-induced rat hepatic cancer. Cancer Res 1982;42:2857-60.
12. Reiss M, Maniglia CA, Sartorelli AC. Modulation of cell shedding and glycosaminoglycan synthesis of human malignant keratinocytes by all-trans-retinoic acid and hydrocortisone in vitro. J Invest Dermatol 1986;86:683-8.
13. Martins JR, Gadelha ME, Fonseca SM, Sampaio LO, De L Pontes PA, Dietrich CP et al. Patients with head and neck tumors excrete a chondroitin sulfate with a low degree of sulfation: a new tool for diagnosis and follow-up of cancer therapy. Otolaryngol Head Neck Surg 2000;122:115-8.
14. Sugahara K, Okumura Y, Yamashina I. The Engelbreth-Holm-Swarm mouse tumor produces undersulfated heparan sulfate and oversulfated galactosaminoglycans. Biochem Biophys Res Commun 1989;162:189-97.
15. Robinson J, Viti M, Hook M. Structure and properties of an under-sulfated heparan sulfate proteoglycan synthesized by a rat hepatoma cell line. J Cell Biol 1984;98:946-53.
16. Adany R, Heimer R, Caterson B, Sorrell JM, Iozzo RV. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 1990;265:11389-96.
17. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001;7:1299-305.
18. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005;280:12103-13.
19. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 2004;22:1-6.
20. Zvibel I, Halay E, Reid LM. Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors. Mol Cell Biol 1991;11:108-16.
21. Jemth P, Kreuger J, Kusche-Gullberg M, Sturiale L, Gimenez-Gallego G, Lindahl U. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF) 1 and FGF2 binding. J Biol Chem 2002;277:30567-73.
22. Moczar M, Caux F, Bailly M, Berthier O, Dore JF. Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability. Clin Exp Metastasis 1993;11:462-71.
23. Desnoyers L. Structural basis and therapeutic implication of the interaction of CCN proteins with glycoconjugates. Curr Pharm Des 2004;10:3913-28.
24. Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 1995;270:16871-8.
25. Levy P, Robert A, Picard J. Biosynthesis of glycosaminoglycans in the human colonic tumor cell line Caco-2: structural changes occurring with the morphological differentiation of the cells. Biol Cell 1988;62:255-64.
26. Molist A, Romaris M, Lindahl U, Villena J, Touab M, Bassols A. Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. Eur J Biochem 1998;254:371-7.
27. Salmivirta M, Safaiyan F, Prydz K, Andresen MS, Aryan M, Kolset SO. Differentiation-associated modulation of heparan sulfate structure and function in CaCo-2 colon carcinoma cells. Glycobiology 1998;8:1029-36.
28. Margolis RK, Salton SR, Margolis RU. Effects of nerve growth factor-induced differentiation on the heparan sulfate of PC12 pheochromocytoma cells and comparison with developing brain. Arch Biochem Biophys 1987;257:107-14.
29. Timar J, Diczhazi C, Bartha I, Pogany G, Paku S, Raso E et al. Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. Int J Cancer 1995;62:755-61.
30. Steck PA, Cheong PH, Nakajima M, Yung WK, Moser RP, Nicolson GL. Altered expression of glycosaminoglycans in metastatic 13762NF rat mamma adenocarcinoma cells. Biochemistry 1987;26:1020-8.
31. Brunner G, Reimbold K, Meissauer A, Schirrmacher V, Erkell LJ. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. Exp Cell Res 1998;239:301-10.
32. Bertolesi GE, Farias EF, Alonso DF, Bal de Kier JE, Lauria de Cidre S, Eijan AM. Insight into the profibrinolytic activity of heparin: effects on the activation of plasminogen mediated by urokinase. Blood Coagul Fibrinolysis 1997;8:403-10.
33. Stephens RW, Pollanen J, Tapiovaara H, Woodrow G, Vaheri A. Stimulation of cell surface plasminogen activation by heparin and related polyionic substances. Semin Thromb Hemostasis 1991;17:201-9.
34. Stephens RW, Bokman AM, Myohanen HT, Reisberg T, Tapiovaara H, Pedersen N et al. Heparin binding to the urokinase kringle domain. Biochemistry 1992;31:7572-9.
35. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59:3433-41.
36. Murata J, Saiki I, Makabe T, Tsuta Y, Tokura S, Azuma I. Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res 1991;51:22-6.
37. Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O et al. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin. Isr J Med Sci 1995;31:106-18.
38. Makabe T, Saiki I, Murata J, Ohdate Y, Kawase Y, Taguchi Y et al. Modulation of haptotactic migration of metastatic melanoma cells by the interaction between heparin and heparin-binding domain of fibronectin. J Biol Chem 1990;265:14270-6.
39. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93-106.
40. Saiki I, Murata J, Nakajima M, Tokura S, Azuma I. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res 1990;50:3631-7.
41. McCarthy JB, Skubitz AP, Qi Z, Yi XY, Mickelson DJ, Klein DJ et al. RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and - independent activities. J Cell Biol 1990;110:777-87.
42. Da Silva MS, Horton JA, Wijelath JM, Blystone LW, Fish WR, Wijelath E et al. Heparin modulates integrin-mediated cellular adhesion: specificity of interactions with alpha and beta integrin subunits. Cell Commun Adhes 2003;10:59-67.
43. Dvorak HF. Wounds that do not heal-similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
44. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 2003;1:1456-63.
45. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82:1101-4.
46. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502-9.
47. Pepe G, Giusti B, Attanasio M, Gori AM, Comeglio P, Martini F et al. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin Thromb Hemost 1997;23:135-41.
48. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-93.
49. Liu HM, Wang DL, Liu CY. Interactions between fibrin, collagen and endothelial cells in angiogenesis. Adv Exp Med Biol 1990;281:319-31.
50. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993;264:C1302-7.
51. Van Hinsbergh VW, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 1997;79:391-411.
52. Chen YQ, Trikha M, Gao X, Bazaz R, Porter AT, Timar J et al. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 1997;72:642-8.
53. Trikha M, Raso E, Cai Y, Fazakas Z, Paku S, Porter AT et al. Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate 1998;35:185-92.
54. Trikha M, Timar J, Lundy SK, Szekeres K, Cai Y, Porter AT et al. The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells. Cancer Res 1997;57:2522-8.
55. Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, van Noorden CJF et al. The effects of unfractionated and low molecular weight heparins on microvascular endothelial cell proliferation and formation of capillary-like tubular structures in a fibrin matrix. Cancer Res 2000;60:6196-200.
56. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997;75:9-16.
57. Pisano C, Aulicino C, Vesci L, Casu B, Naggi A, Torri G et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005;15:1C-6C.
58. Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993;23:141-9.
59. Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 1996;16:8-15.
60. Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int J Microcirc Clin Exp 1997;17:314-21.
61. Lepri A, Benelli U, Bernardini N, Bianchi F, Lupetti M, Danesi R et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 1994;10:273-80.
62. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005;24:4037-51.